PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | The NEW ENGLAND JOURNAL Of MEDICINE

Authors: Andrea Cercek, M.D., Melissa Lumish, M.D. https://orcid.org/0000-0003-4173-5567, Jenna Sinopoli, N.P., Jill Weiss, B.A., Jinru Shia, M.D., MichelleLamendola-Essel, D.H.Sc., Imane H. El Dika, M.D., and Luis A. Diaz, Jr., M.D.

BACKGROUND

Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair–deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair–deficient, locally advanced rectal cancer.

METHODS

We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti–PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair–deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery. Patients who had a clinical complete response after completion of dostarlimab therapy would proceed without chemoradiotherapy and surgery. The primary end points are sustained clinical complete response 12 months after completion of dostarlimab therapy or pathological complete response after completion of dostarlimab therapy with or without chemoradiotherapy and overall response to neoadjuvant dostarlimab therapy with or without chemoradiotherapy.
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

RESULTS

A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose–positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported.

CONCLUSIONS

Mismatch repair–deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response. (Funded by the Simon and Eve Colin Foundation and others; ClinicalTrials.gov number, NCT04165772.)
Locally advanced rectal cancer is typically managed with multimodal therapy, including chemotherapy, radiation, and surgery. Current evidence supports a strategy involving the use of neoadjuvant therapy, in which induction chemotherapy with a fluoropyrimidine in combination with oxaliplatin is followed by chemoradiotherapy and then surgery.1-3 This approach results in a pathological complete response in up to a quarter of patients, but it is associated with marked complications and toxic effects — including bowel, urinary, and sexual dysfunction; infertility; and altered quality of life — in a substantial proportion of patients.4-6 In patients undergoing surgery, resection of the rectum is life-altering and often warrants a permanent diverting colostomy.6,7 Owing to the complications of surgery and the high frequency of pathological complete response, interest in organ-sparing nonoperative management is increasing. The use of clinical complete response that is achieved with neoadjuvant treatment as a surrogate for pathological complete response provides patients with a nonoperative option that results in a survival benefit that is similar to that in patients undergoing surgical resection.8-11
Approximately 5 to 10% of rectal adenocarcinomas are mismatch-repair deficient, and these tumors have been shown to respond poorly to standard chemotherapy regimens, including neoadjuvant chemotherapy in locally advanced rectal cancer.12-14 Immune checkpoint blockade alone has been shown to be highly effective as first-line treatment for patients with mismatch repair–deficient metastatic colorectal cancer, as well as for patients with treatment-refractory disease, with objective response rates of 33 to 55%, clinically significant durability of response, and prolonged overall survival.15-17
On the basis of the benefits seen in the context of metastatic disease, we hypothesized that single-agent programmed death 1 (PD-1) blockade alone might be beneficial in mismatch repair–deficient, locally advanced rectal cancer. To test this hypothesis, we initiated a phase 2 study to investigate the overall response and frequency of sustained clinical complete response to neoadjuvant treatment with dostarlimab, a PD-1 inhibitor, in this patient population.

Skip The Scoop | Seek Understanding

In Lady Bird Johnson’s Secret Diaries, a Despairing President and a Crucial Spouse

Show Me

European Countries Suspend Use of AstraZeneca Shots Over Worries About Blood Clots

Show Me

Denmark, Norway, Iceland Suspend AstraZeneca COVID Shots After Blood Clot Reports

Show Me

Updates on CCP Virus: Bulgaria Halts AstraZeneca Vaccine Rollout, Citing Safety Concerns

Show Me

Live Q&A: Virus Origin Story Gets Narrative Shift; $5000 Fines Proposed for Online “Conspiracies”

Show Me

YouTube Has Removed Over 800,000 Videos Containing Misleading COVID-19 Information: Spokesperson

Show Me

Biden slammed for taking credit for COVID-19 vaccine, not thanking Trump

Show Me

Mich. lawmaker: Time to use subpoena to learn Whitmer secrets about COVID nursing home deaths

Show Me

These ‘Inactive’ Ingredients in COVID Vaccines Could Trigger Allergic Reactions

Show Me

Medical Examiner Not Jumping to Conclusions After Utah Mom Dies Following COVID-19 Vaccination

Show Me

COVID-19: Pharmaceutical companies and rich states put lives at risk as vaccine inequality soars

Show Me

Mexican Cartels Overcome Pandemic Hurdles to Remain Greatest Criminal Drug Threat to U.S.

Show Me

Medical examiner says Kassidi Kurill’s death likely wasn’t caused by Moderna vaccine

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded March 12, 2021 | Video: 48 Minutes 53 Seconds

Show Me

EXC: Bill Gates Foundation Funded Genomics Firm ‘Mining’ DNA Data Through COVID Tests.

Show Me

The Case for Covid Optimism

Show Me

Bannon’s War Room | Evening Edition | Recorded March 12, 2021 | Video: 49 Minutes

Show Me

School in NYC Asks Students Not to Use “Mom and Dad”

Show Me

3 Deaths in 9 Days After Hongkongers Get China’s Sinovac Vaccine

Show Me

How ‘Woke Capitalism’ In Big Business Is Pushing A Radical Agenda—Interview with Stephen Soukup

Show Me

More than 90 Montana legislators sign letter opposing cancellation of Keystone XL Pipeline project

Show Me

AG Garland Vows to Uphold One Standard of Justice in First Speech at DOJ

Show Me

Norway Wealth Fund to Probe Whether Firms Could Be Using Forced Labour From China’s Xinjiang

Show Me

Montana Man Pleads Guilty for Lying Over Explosion Incident That Killed a Marine Veteran

Show Me

March 11, 2021 | Nightly News Rebroadcast | Video: 51 Minutes 53 Seconds

Show Me

Louisiana Man Killed After Attempting to Sell Dirt Bike on Facebook Marketplace

Show Me

UN investigator finds Iran responsible for ‘egregious’ human rights violations

Show Me

Pfizer Demands Nations Put Up Collateral to Cover Vaccine Injury Lawsuits

Show Me

12 Prominent Scientists and Doctors to EU Regulators: Address ‘Urgent’ Safety Concerns or Halt COVID Vaccines

Show Me

Minneapolis ‘Autonomous Zone’ a Danger to Residents and Businesses: National Police Association

Show Me

Michigan prosecutor says will restart review board to probe COVID nursing home deaths under Whitmer

Show Me

Roger Mudd, Longtime Network TV Newsman, Dies at 93

Show Me

Texas court rules Planned Parenthood can be removed from state’s Medicaid program

Show Me

COVID Vaccine Injuries — What’s the Financial Risk?

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded March 11, 2021 | Video: 48 Minutes 58 Seconds

Show Me

39-Year-Old Woman Dies 4 Days After Second Moderna Vaccine, Autopsy Ordered

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded March 11, 2021 | Video: 48 Minutes 30 Seconds

Show Me

LA Schools to Track Every Kid Using Microsoft’s ‘Daily Pass’ COVID App

Show Me

Bannon’s War Room | Evening Edition | Recorded March 11, 2021 | Video: 49 Minutes

Show Me

March 10, 2021 | Nightly News Rebroadcast | Video: 51 Minutes 53 Seconds

Show Me